Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein

PLoS Medicine

Volumn 4, Issue 11, 2007, Pages 1791-1803

  Roussilhon, Christian ^a   Oeuvray, Claude ^a   Müller Graf, Christine ^b   Tall, Adama ^c   Rogier, Christophe ^c,d   Trape, Jean François ^e   Theisen, Michael ^f   Balde, Aissatou ^c   Pérignon, Jean Louis ^a   Druilhe, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT PASTEUR DE DAKAR   (Senegal)

^d SERVICE DE SANTÉ DES ARMÉES   (France)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^f STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; APICAL MEMBRANE ANTIGEN 1; EPITOPE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MALARIA VACCINE; MEMBRANE ANTIGEN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; QUINIMAX; QUININE; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; PROTOZOAL PROTEIN;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CHILD CARE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DRUG HALF LIFE; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; INNATE IMMUNITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MOSQUITO; OUTCOME ASSESSMENT; PARAMETER; PROTEIN DETERMINATION; SICKLE CELL TRAIT; ANIMAL; BLOOD; DNA SEQUENCE; EPIDEMIOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INFANT; MEROZOITE; MOLECULAR GENETICS; NEWBORN; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; SENEGAL;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; EPITOPES; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEROZOITES; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SENEGAL; SEQUENCE ANALYSIS, DNA; SEROEPIDEMIOLOGIC STUDIES;

EID: 36849011566     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040320     Document Type: Article

References (80)

1. Graves P, Gelband H (2003) Vaccines for preventing malaria. Cochrane Database Syst Rev: CD000129.
2. Webster D, Hill AV (2003) Progress with new malaria vaccines. Bull World Health Organ 81: 902-909.
3. Druilhe P, Hagan P, Rook GA (2002) The importance of models of infection in the study of disease resistance. Trends Microbiol 10: S38-46.
4. Taylor-Robinson AW (2002) A model of development of acquired immunity to malaria in humans living under endemic conditions. Med Hypotheses 58: 148-156.
5. Cohen S, Mc Gregor A, Carrington S (1961) Gamma globulin and acquired immunity to human malaria. Nature 192: 733-737.
6. Bouharoun-Tayoun H, Attanah P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P (1990) Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
7. Rogier C, Commenges D, Trape J (1996) Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. Amer J Trop Med Hyg 54: 613-619.
8. Gatton ML, Cheng Q (2002) Evaluation of the pyrogenic threshold for Plasmodium falciparum malaria in naive individuals. Am J Trop Med Hyg 66: 467-473.
9. Boutlis CS, Weinberg JB, Baker J, Bockarie MJ, Mgone CS, et al. (2004) Nitric oxide production and nitric oxide synthase activity in malaria-exposed Papua New Guinean children and adults show longitudinal stability and no association with parasitemia. Infect Immun 72: 6932-6938.
10. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM (1999) Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 21: 133-139.
11. Okoyeh JN, Pillai CR, Chitnis CE (1999) Plasmodium falciparum field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A. Infect Immun 67: 5784-5791.
12. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. (2000) Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 38: 706-718.
13. Casey JL, Coley AM, Anders RF, Murphy VJ, Humberstone KS, et al. (2004) Antibodies to malaria peptide mimics inhibit Plasmodium falciparum invasion of erythrocytes. Infect Immun 72: 1126-1134.
14. Contreras CE, Santiago JI, Jensen JB, Udeinya IJ, Bayoumi R, et al. (1988) RESA-IFA assay in Plasmodium falciparum malaria, observations on relationship between serum antibody titers, immunity, and antigenic diversity. J Parasitol 74: 129-134.
15. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182: 409-418.
16. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, et al. (1994) The Dielmo project. A longitudinal study of natural malaria infection in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 51: 123-137.
17. Rogier C (2000) Natural history of Plasmodium falciparum malaria and determining factors of the acquisition of antimalaria immunity in two endemic areas, Dielmo and Ndiop (Senegal). Bull Mem Acad R Med Belg 155: 218-226.
18. McGuinness D, Koram K, Bennett S, Wagner G, Nkrumah F, et al. (1998) Clinical case definitions for malaria: clinical malaria associated with very low parasite densities in African infants. Trans R Soc Trop Med Hyg 92: 527-531.
19. Bouvier P, Rougemont A, Breslow N, Doumbo O, Delley V, et al. (1997) Seasonality and malaria in a west African village: does high parasite density predict fever incidence? Am J Epidemiol 145: 850-857.
20. Smith T, Schellenberg JA, Hayes R (1994) Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 13: 2345-2358.
21. Trape J, Peelman P, Morault-Peelman B (1985) Criteria for diagnosing clinical malaria among a semi-immune population exposed to intense and perennial transmission. Trans Roy Soc Trop Med Hyg 79: 435-442.
22. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. (1994) Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
23. Singh S, Soe S, Mejia JP, Roussilhon C, Theisen M, et al. (2004) Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 190: 1010-1018.
24. McColl D, Anders R (1997) Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 90: 21-31.
25. Huber W, Felger I, Matile H, Lipps H, Steiger S, et al. (1997) Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol 87: 231-234.
26. Chappel J-A, Egan AF, Riley EM, Druilhe P, Holder AA (1994) Naturally acquired human antibodies which recognise the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein-1 do not inhibit parasite growth in vitro. Infec Immun 62: 4488-4494.
27. Thomas A, Trape J, Rogier C, Goncalves A, Rosario V, et al. (1994) High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Amer J Trop Med Hyg 51: 730-740.
28. Rzepczyk CM, Hale K, Woodroffe N, Bobogare A, Csurhes P, et al. (1997) Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 Subclass. Infec Immun; 65: 1098-1100.
29. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, Benmohamed L, et al. (1994) Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 153: 190-204.
30. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, et al. (2000) Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 6: 1258-1263.
31. Brown AE, Webster HK, Gordon DM, Permpanich B, Gross M (1992) Characterization of naturally acquired antibodies to the non-repetitive flanking regions of the circumsporozoite protein of Plasmodium falciparum. Am J Trop Med Hyg 47: 440-445.
32. Bouharoun-Tayoun H, Druilhe P (1992) Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60: 1473-1481.
33. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, et al. (1998) The glutamate-rich protein (Glurp) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infec Immun 66: 11-17.
34. Petersen E, Borre M, Vuust J (1991) Allele specific analysis of Plasmodium falciparum genes by the polymerase chain reaction. Mol Immunol 28: 183-184.
35. Kocherlakota S, Kocherlakota K (1992) Bivariate discrete distributions. Marcel Dekker. Monticello (NY): Marcel Dekker. 361 p.
36. Rogier C, Ly AB, Tall A, Cisse B, Trape JF (1999) Plasmodium falciparum clinical malaria in Dielmo, a holoendemic area in Senegal: no influence of acquired immunity on initial symptomatology and severity of malaria attacks. Am J Trop Med Hyg 60: 410-420.
37. Marsh K, Snow RW (1999) Malaria transmission and morbidity. Parassitologia 41: 241-246.
38. Taylor RR, Allen SJ, Greenwood BM, Riley EM (1998) IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 58: 406-413.
39. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
40. al-Yaman F, Genton B, Anders R, Taraika J, Ginny M, et al. (1995) Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol 17: 493-501.
41. Chizzolini C, Dupont A, Akue JP, Kaufmann MH, Verdini AS, et al. (1988) Natural antibodies against three distinct and defined antigens of Plasmodium falciparum in residents of a mesoendemic area in Gabon. Am J Trop Med Hyg 39: 150-156.
42. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, et al. (2005) Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 191: 264-271.
43. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM (1989) Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 83: 293-303.
44. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, et al. (2000) Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 181: 1202-1205.
45. Topolska AE, Richie TL, Nhan DH, Coppel RL (2004) Associations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infection. Infect Immun 72: 3325-3330.
46. Bouharoun-Tayoun H, Druilhe P (1992) Antibodies in falciparum malaria: what matters most, quantity or quality? Mem Inst Oswaldo Cruz, Rio de Janeiro 87: 229-234.
47. Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, et al. (2004) Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol 52: 159-168.
48. Sakihama N, Matsuo T, Mitamura T, Horii T, Kimura M, et al. (2004) Relative frequencies of polymorphisms of variation in block 2 repeats and 5′ recombinant types of Plasmodium falciparum msp1 alleles. Parasitol Int 53: 59-67.
49. Aubouy A, Migot-Nabias F, Deloron P (2003) Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J 2: 12.
50. Escalante AA, Grebert HM, Chaiyaroj SC, Magris M, Biswas S, et al. (2001) Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol 113: 279-287.
51. de Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M (2000) Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 111: 123-130.
52. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, et al. (2003) Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 25: 307-312.
53. Sergent ED, Parrot L (1935) L'immunité, la prémunition et la résistance innée. Archives de l'institut Pasteur d'Algérie TXIII: 279-319.
54. Rogier C, Trape JF (1993) Malaria attacks in children exposed to high transmission: who is protected? Trans R Soc Trop Med Hyg 87: 245-246.
55. Aribot G, Rogier C, Sarthou JL, Trape JF, Balde AT, et al. (1996) Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, West Africa). Am J Trop Med Hyg 54: 449-457.
56. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, et al. (2000) Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68: 2617-2620.
57. Okech BA, Nalunkuma A, Okello D, Pang XL, Suzue K, et al. (2001) Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda. Am J Trop Med Hyg 65: 912-917.
58. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P (2004) Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72: 247-252.
59. Okenu DM, Riley EM, Bickle QD, Agomo PU, Barbosa A, et al. (2000) Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun 68: 5559-5566.
60. John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW (2003) Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 71: 4320-4325.
61. Meraldi V, Nebie I, Tiono AB, Diallo D, Sanogo E, et al. (2004) Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 26: 265-272.
62. Beck HP, Felger I, Genton B, Alexander N, al-Yaman F, et al. (1995) Humoral and cell-mediated immunity to the Plasmodium falciparum ring-infected erythrocyte surface antigen in an adult population exposed to highly endemic malaria. Infect Immun 63: 596-600.
63. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, et al. (2000) A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 6: 689-692.
64. de Koning-Ward TF, O'Donnell RA, Drew DR, Thomson R, Speed TP, et al. (2003) A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 198: 869-875.
65. Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, et al. (2004) Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun 72: 6492-6502.
66. al-Yaman F, Genton B, Kramer K, Chang S, Hui G, et al. (1996) Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 54: 443-448.
67. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, et al. (1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173: 765-769.
68. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, et al. (2004) Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 173: 666-672.
69. Polley SD, Tetteh KK, Lloyd JM, Akpogheneta OJ, Greenwood BM, et al. (2007) Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 195: 279-287.
70. Badell E, Oeuvray C, Moreno A, Soe S, van Rooijen N, et al. (2000) Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med 192: 1653-1660.
71. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, et al. (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2: e344. doi:10.1371/journal.pmed.0020344
72. Lundquist R, Nielsen LK, Jafarshad A, Soesoe D, Christensen LH, et al. (2006) Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun 74: 3222-3231.
73. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, et al. (2007) A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 178: 3099-3106.
74. Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, et al. (2002) Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 185: 657-664.
75. Druilhe P, Perignon JL (1997) A hypothesis about the chronicity of malaria infection. Parasitol Today 13: 353-357.
76. Saul A (2007) Malaria vaccines based on the Plasmodium falciparum merozoite surface protein 3-should we avoid amino acid sequence polymorphisms or embrace them? J Infect Dis 195: 171-173.
77. Singh S, Soe S, Roussilhon C, Corradin G, Druilhe P (2005) Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing. Infect Immun 73: 1235-1238.
78. Mills KE, Pearce JA, Crabb BS, Cowman AF (2002) Truncation of merozoite surface protein 3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of Plasmodium falciparum merozoites. Mol Microbiol 43: 1401-1411.
79. Oeuvray C, Bouharoun-Tayoun H, Filgueira M-C, Gras-Masse H, Tartar A, et al. (1993) Characterization of a Plasmodium falciparum merozoite surface antigen targeted by defense mechanisms developped in immune individuals. CR Acad Sci Paris 316: 395-399.
80. Audran R, Cachat M, Lurati F, Soe S, Leroy O, et al. (2005) Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73: 8017-8026.